<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; cancer</title>
	<atom:link href="http://www.tapanray.in/tag/cancer/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Setting A Cost Of Time That Patients May Gain From A New Therapy</title>
		<link>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy</link>
		<comments>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/#comments</comments>
		<pubDate>Mon, 16 Mar 2020 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[calculation]]></category>
		<category><![CDATA[calculator]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cost of time]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[prolonging]]></category>
		<category><![CDATA[quality of life]]></category>
		<category><![CDATA[quantity of life]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[setting]]></category>
		<category><![CDATA[Spiranza]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9916</guid>
		<description><![CDATA[Since quite some, an intense ongoing debate about setting a cost of time, often by a few months, that patients could possibly gain from a new therapy for complex diseases. The answer still remains elusive.  Meanwhile, newer therapies for treating cancer, &#8230; <a href="http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dynamics of Cancer Therapy Segment Remain Enigmatic</title>
		<link>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dynamics-of-cancer-therapy-segment-remain-enigmatic</link>
		<comments>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/#comments</comments>
		<pubDate>Mon, 14 Oct 2019 00:00:17 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Assistance]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[day]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[enigma]]></category>
		<category><![CDATA[enigmatic]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[PAP]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[program]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UICC]]></category>
		<category><![CDATA[Union for International Cancer Control]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9745</guid>
		<description><![CDATA[Currently, cancer is likely to occupy the center stage on any discussion related to the fastest growing therapy segments in the pharma or biotech industries. There are several reasons behind such probability, some of which include: Cancer is not only &#8230; <a href="http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dynamics-of-cancer-therapy-segment-remain-enigmatic/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Facet of ‘Data Integrity’ With Novel Therapy… And Much Beyond</title>
		<link>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond</link>
		<comments>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/#comments</comments>
		<pubDate>Mon, 30 Sep 2019 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AveXis]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[cherry-picking]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9728</guid>
		<description><![CDATA[The peril of breach of data integrity involving a top Indian pharma player, jolted many, probably for the first time, on September 17, 2008. On that day, the USFDA, reportedly, issued two ‘Warning Letters’ and an ‘Import Alert’. These were related to &#8230; <a href="http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Would ‘Connected Healthcare’ Catch Pharma Players Off-Guard?</title>
		<link>http://www.tapanray.in/would-connected-healthcare-catch-pharma-players-off-guard/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=would-connected-healthcare-catch-pharma-players-off-guard</link>
		<comments>http://www.tapanray.in/would-connected-healthcare-catch-pharma-players-off-guard/#comments</comments>
		<pubDate>Mon, 08 Apr 2019 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Apple]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cHealth]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[connected]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[e-health]]></category>
		<category><![CDATA[e-prescription]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Internet of Things]]></category>
		<category><![CDATA[IoT]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mHealth]]></category>
		<category><![CDATA[mobile]]></category>
		<category><![CDATA[MRI]]></category>
		<category><![CDATA[off-guard]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[shared]]></category>
		<category><![CDATA[symptoms]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[threatening]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9474</guid>
		<description><![CDATA[Rapid advancement of medical science is making several life-threatening diseases easily preventable, curable and manageable. For some conditions, such as, peptic ulcer even surgical interventions are no longer necessary. This results in the expansion of preventive and primary-care segments, with &#8230; <a href="http://www.tapanray.in/would-connected-healthcare-catch-pharma-players-off-guard/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/would-connected-healthcare-catch-pharma-players-off-guard/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Are Cancer Patients Victims of Pharma’s Payment to Doctors &#8211; For Prescriptions?</title>
		<link>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions</link>
		<comments>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/#comments</comments>
		<pubDate>Mon, 04 Mar 2019 00:00:59 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Catering]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Evaluation]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pay]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[relatioship]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9432</guid>
		<description><![CDATA[In pharma industry, people of all socioeconomic backgrounds have no other choice but to visit doctors, to seek their expert advice for medical treatment. Patients expect them to prescribe the right and most affordable medicines for desired relief. Ironically, it &#8230; <a href="http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/are-cancer-patients-victims-of-pharmas-payment-to-doctors-for-prescriptions/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma’s Oncology Focus: Some Key Drivers With Pros And Cons For Patients</title>
		<link>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients</link>
		<comments>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/#comments</comments>
		<pubDate>Mon, 28 Jan 2019 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Bristol]]></category>
		<category><![CDATA[Bristol-Myers Squibb]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Celgene]]></category>
		<category><![CDATA[cons]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[Myers]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[pros]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[TRK inhibitor]]></category>
		<category><![CDATA[Vitrakvi]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9391</guid>
		<description><![CDATA[Just in the first ten days of the brand-new year &#8211; 2019, three important oncology focused acquisitions were announced by three top global pharma companies. On January 03, 2019, Bristol-Myers Squibb announced that it will acquire Celgene for a hefty sum of USD &#8230; <a href="http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharmas-oncology-focus-some-key-drivers-with-pros-and-cons-for-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>&#8216;Made-to-Measure&#8217; Marketing for &#8216;Made-to-Measure&#8217; Medicines</title>
		<link>http://www.tapanray.in/made-to-measure-marketing-for-made-to-measure-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=made-to-measure-marketing-for-made-to-measure-medicines</link>
		<comments>http://www.tapanray.in/made-to-measure-marketing-for-made-to-measure-medicines/#comments</comments>
		<pubDate>Mon, 26 Mar 2018 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['Made-to-Measure']]></category>
		<category><![CDATA[ball]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[dosage]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Precision]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8867</guid>
		<description><![CDATA[We have entered into a new era of innovation in medical science where ‘one size fits all’ type of treatment is making a sizeable space for a new ‘made-to-measure’ variety of the same. Such medicines are being developed particularly for &#8230; <a href="http://www.tapanray.in/made-to-measure-marketing-for-made-to-measure-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/made-to-measure-marketing-for-made-to-measure-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Emerging Role of Digital Pathology in Cancer</title>
		<link>http://www.tapanray.in/emerging-role-of-digital-pathology-in-cancer/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=emerging-role-of-digital-pathology-in-cancer</link>
		<comments>http://www.tapanray.in/emerging-role-of-digital-pathology-in-cancer/#comments</comments>
		<pubDate>Sun, 31 Dec 2017 23:59:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Barshi]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[incidence]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[Nargis Dutt Memorial Cancer Hospital (NDMCH)]]></category>
		<category><![CDATA[pathology]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Tata]]></category>
		<category><![CDATA[tele pathology]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8677</guid>
		<description><![CDATA[Dear readers, an unlocked door awaiting all of us with tons of opportunities as we log out of  2017 and log in to 2018. Let&#8217;s grab those, bringing changes and smile  in many lives. Happy New Year Cancer is now &#8230; <a href="http://www.tapanray.in/emerging-role-of-digital-pathology-in-cancer/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/emerging-role-of-digital-pathology-in-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>High Innovation-Cost Makes Cancer Drugs Dear: A Fragile Argument?</title>
		<link>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument</link>
		<comments>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/#comments</comments>
		<pubDate>Mon, 18 Sep 2017 00:00:55 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[17]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[argument]]></category>
		<category><![CDATA[Bill]]></category>
		<category><![CDATA[bust]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[Chief]]></category>
		<category><![CDATA[CM]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[dear]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[fragile]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[innovation-cost]]></category>
		<category><![CDATA[intensive]]></category>
		<category><![CDATA[jeopardizing]]></category>
		<category><![CDATA[Keytruda]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[policymakers]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[Senate]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technological]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tribe]]></category>
		<category><![CDATA[unaffordable]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8417</guid>
		<description><![CDATA[Cancer is a major cause of high morbidity and mortality in India, just many other countries, according to a report of the World Health Organization (W.H.O). While deaths from cancer worldwide are projected to continue to rise to over 1.31 &#8230; <a href="http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/high-innovation-cost-makes-cancer-drugs-dear-a-fragile-argument/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dawns A New Era: Regenerative Medicine For Degenerative Disease</title>
		<link>http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dawns-a-new-era-regenerative-medicine-for-degenerative-disease</link>
		<comments>http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/#comments</comments>
		<pubDate>Mon, 17 Jul 2017 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Alzheimer's]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cells]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[degeneration]]></category>
		<category><![CDATA[degenerative]]></category>
		<category><![CDATA[diabetes]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[Heart]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[ischemia]]></category>
		<category><![CDATA[Macular]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[multiple]]></category>
		<category><![CDATA[Parkinson's]]></category>
		<category><![CDATA[patch]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regenerative]]></category>
		<category><![CDATA[sclerosis]]></category>
		<category><![CDATA[stem]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8321</guid>
		<description><![CDATA[Could breakthrough innovation in ‘Regenerative Medicine’ significantly reduce the need of expensive lifelong medications, or even make the use of some important medical devices less relevant, or even help avoiding expensive and risky surgical interventions? The common answer to these &#8230; <a href="http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dawns-a-new-era-regenerative-medicine-for-degenerative-disease/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
